RUEMU E BIRHIRAY
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- NOBLESVILLE, IN
- NPI
- 1295735058
- Received
- $3,059,023 in 3,577 records, 2019 to 2025 ($3,055,048 general, $3,975 research)
- As principal investigator
- $895,202 of research payments to others in 215 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 556 | $434,603 |
| 2025 | Research payment | 2 | $1,101 |
| 2024 | General payment | 610 | $483,693 |
| 2024 | Research payment | 8 | $2,874 |
| 2023 | General payment | 674 | $542,099 |
| 2022 | General payment | 508 | $480,517 |
| 2021 | General payment | 376 | $475,055 |
| 2020 | General payment | 265 | $237,046 |
| 2019 | General payment | 578 | $402,031 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 772 | $2,132,360 |
| Travel and Lodging | 676 | $417,593 |
| Consulting Fee | 170 | $340,197 |
| Food and Beverage | 1,877 | $75,257 |
| Honoraria | 23 | $48,842 |
| Compensation for serving as faculty or as a speaker for a medical education program | 15 | $38,530 |
| Research payment | 10 | $3,975 |
| Long term medical supply or device loan | 14 | $1,297 |
| Education | 20 | $968 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-23 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Hyrnuo Drug, Oncology | 2025 | |
| 2025-12-22 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-12-18 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-12-18 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-12-17 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-12-16 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JAYPIRCA Drug, Oncology | 2025 | |
| 2025-12-15 | Janssen Biotech, Inc. | $3,607 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-12 | AstraZeneca Pharmaceuticals LP | $25 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-12-12 | Gilead Sciences, Inc. | $21 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-12-11 | GlaxoSmithKline, LLC. | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-12-11 | Janssen Biotech, Inc. | $121 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-08 | Janssen Biotech, Inc. | $39 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-12-08 | Amneal Pharmaceuticals LLC | $17 | Food and Beverage | In-kind items and services | PEMRYDI RTU Drug, ONCOLOGY | 2025 | |
| 2025-12-07 | Genmab U.S., Inc. | $112 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-12-06 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2025 | |
| 2025-12-05 | GlaxoSmithKline, LLC. | $120 | Food and Beverage | In-kind items and services | BLENREP Biological, ONCOLOGY | 2025 | |
| 2025-12-03 | Incyte Corporation | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | Incyte Corporation | $2,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-12-03 | Amgen Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMDELLTRA (AMG757) Biological, Hematology | 2025 | |
| 2025-12-02 | EMD Serono, Inc. | $24 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-02 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-12-02 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-12-02 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-12-02 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-11-25 | Gilead Sciences, Inc. | $30 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-11-25 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | CARVYKTI Drug, Oncology | 2025 | |
| 2025-11-24 | Incyte Corporation | $2,055 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Jakafi Drug, Hematology/Oncology | 2025 | |
| 2025-11-21 | Daiichi Sankyo Inc. | $24 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-11-21 | Acrotech Biopharma Inc. | $16 | Food and Beverage | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2025 | |
| 2025-11-21 | GlaxoSmithKline, LLC. | $13 | Food and Beverage | In-kind items and services | BLENREP Biological, ONCOLOGY | 2025 | |
| 2025-11-20 | Aveo Pharmaceuticals, Inc. | $20 | Education | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-11-19 | Aveo Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-11-18 | GlaxoSmithKline, LLC. | $50 | Travel and Lodging | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-18 | Caris MPI, Inc. | $33 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-11-18 | SERVIER PHARMACEUTICALS LLC | $16 | Food and Beverage | In-kind items and services | Tibsovo Drug, Oncology | 2025 | |
| 2025-11-17 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-17 | GlaxoSmithKline, LLC. | $475 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-15 | Genmab U.S., Inc. | $49 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-15 | Genmab U.S., Inc. | $34 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-15 | Genmab U.S., Inc. | $25 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-14 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-11-14 | AstraZeneca Pharmaceuticals LP | $5,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-11-14 | Janssen Biotech, Inc. | $1,606 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-14 | Genmab U.S., Inc. | $363 | Travel and Lodging | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-11-14 | E.R. Squibb & Sons, L.L.C. | $26 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-13 | Janssen Biotech, Inc. | $125 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-13 | Rigel Pharmaceuticals, Inc. | $18 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $1,675 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | Adaptive Biotechnologies Corporation | $22 | Food and Beverage | Cash or cash equivalent | clonoSEQ Device, Devices | 2025 | |
| 2025-11-11 | Incyte Corporation | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-11 | GlaxoSmithKline, LLC. | $3,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $1,823 | Travel and Lodging | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-11-11 | AstraZeneca Pharmaceuticals LP | $95 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2025 | |
| 2025-11-11 | TerSera Therapeutics LLC | $38 | Food and Beverage | In-kind items and services | Xermelo Drug, Oncology | 2025 | |
| 2025-11-11 | JAZZ PHARMACEUTICALS INC. | $22 | Food and Beverage | In-kind items and services | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | 2025 | |
| 2025-11-10 | SpringWorks Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | GOMEKLI Drug, NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS | 2025 | |
| 2025-11-10 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $421 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $279 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $279 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $273 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $269 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $155 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $155 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-08 | Incyte Corporation | $80 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-11-07 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-11-07 | Lilly USA, LLC | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-11-07 | GlaxoSmithKline, LLC. | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-07 | GlaxoSmithKline, LLC. | $1,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-11-06 | SANOFI US SERVICES INC. | $1,474 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-06 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-11-05 | Exelixis Inc. | $3,960 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-11-04 | Lilly USA, LLC | $1,006 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-04 | Lilly USA, LLC | $96 | Food and Beverage | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-04 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-03 | SANOFI US SERVICES INC. | $4,791 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-03 | SANOFI US SERVICES INC. | $1,407 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-03 | SANOFI US SERVICES INC. | $134 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-03 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-31 | BeOne Medicines USA, Inc. | $1,035 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-31 | GlaxoSmithKline, LLC. | $0 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2025 | |
| 2025-10-30 | BeOne Medicines USA, Inc. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-30 | BeOne Medicines USA, Inc. | $18 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-30 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-29 | Novartis Pharmaceuticals Corporation | $6,700 | Consulting Fee | Cash or cash equivalent | KISQALI Drug, Oncology | 2025 | |
| 2025-10-29 | GlaxoSmithKline, LLC. | $2,224 | Travel and Lodging | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-10-29 | Genmab U.S., Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-10-29 | GlaxoSmithKline, LLC. | $123 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-10-29 | Celgene Corporation | $29 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-10-28 | Incyte Corporation | $1,592 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-28 | Incyte Corporation | $125 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-25 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Phesgo Biological, BioOncology | 2025 | |
| 2025-10-24 | AstraZeneca Pharmaceuticals LP | $6,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-24 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-24 | Lilly USA, LLC | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-10-24 | Lilly USA, LLC | $1,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-10-24 | E.R. Squibb & Sons, L.L.C. | $22 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-24 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-10-24 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-10-23 | Lilly USA, LLC | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-10-23 | Rigel Pharmaceuticals, Inc. | $28 | Food and Beverage | Cash or cash equivalent | TAVALISSE Drug, Hematology | 2025 | |
| 2025-10-23 | Alexion Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-10-22 | Stryker Corporation | $66 | Food and Beverage | In-kind items and services | CLOTTRIEVER BOLD CATHETER Device, INARI MEDICAL | 2025 | |
| 2025-10-22 | Genmab U.S., Inc. | $22 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-10-22 | Janssen Biotech, Inc. | $7 | Food and Beverage | In-kind items and services | TALVEY Biological, Oncology | 2025 | |
| 2025-10-21 | GlaxoSmithKline, LLC. | $5,700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-10-21 | Exelixis Inc. | $3,960 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-10-21 | Lilly USA, LLC | $93 | Food and Beverage | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-10-21 | Karyopharm Therapeutics Inc. | $21 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-10-21 | Kite Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | Yescarta Drug, CELLT | 2025 | |
| 2025-10-21 | pharmaand GmbH | $4 | Food and Beverage | In-kind items and services | Rubraca Drug, PARP inhibitor | 2025 | |
| 2025-10-21 | pharmaand GmbH | $2 | Food and Beverage | In-kind items and services | Rubraca Drug, PARP inhibitor | 2025 | |
| 2025-10-17 | Incyte Corporation | $27 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-10-16 | ABBVIE INC. | $2,887 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-10-16 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-16 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-16 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-10-14 | SANOFI US SERVICES INC. | $4,791 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-10-14 | SANOFI US SERVICES INC. | $1,150 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-10-14 | SANOFI US SERVICES INC. | $129 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-10-14 | Celgene Corporation | $21 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-10-14 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-14 | Janssen Biotech, Inc. | $2 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-14 | Celgene Corporation | $0 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-10-10 | Exelixis Inc. | $1,393 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-10-10 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2025 | |
| 2025-10-10 | Celgene Corporation | $23 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-10-10 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-10-09 | Janssen Biotech, Inc. | $34 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-10-08 | AstraZeneca Pharmaceuticals LP | $1,270 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-08 | AstraZeneca Pharmaceuticals LP | $42 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-10-07 | Incyte Corporation | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-10-07 | Exelixis Inc. | $108 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-10-07 | RECORDATI_RARE_DISEASES_INC. | $21 | Food and Beverage | In-kind items and services | SYLVANT Drug, ONCOLOGIC AGENT | 2025 | |
| 2025-10-07 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | ZEJULA Drug, ONCOLOGY | 2025 | |
| 2025-10-04 | Novartis Pharmaceuticals Corporation | $335 | Travel and Lodging | Cash or cash equivalent | KISQALI Drug, Oncology | 2025 | |
| 2025-10-04 | Novartis Pharmaceuticals Corporation | $228 | Travel and Lodging | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-04 | Novartis Pharmaceuticals Corporation | $69 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-10-03 | Novartis Pharmaceuticals Corporation | $471 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-03 | Novartis Pharmaceuticals Corporation | $364 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-03 | ARRAY BIOPHARMA INC | $20 | Food and Beverage | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2025 | |
| 2025-10-02 | Regeneron Pharmaceuticals, Inc. | $835 | Research payment | In-kind items and services | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBOD | 2025 | |
| 2025-10-01 | SERVIER PHARMACEUTICALS LLC | $15 | Food and Beverage | In-kind items and services | Tibsovo Drug, Oncology | 2025 | |
| 2025-09-30 | GlaxoSmithKline, LLC. | $1,417 | Travel and Lodging | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | GlaxoSmithKline, LLC. | $125 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $24 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $2 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-09-30 | Daiichi Sankyo Inc. | $1 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-09-27 | Geron Corporation | $122 | Food and Beverage | In-kind items and services | RYTELO Drug, MYELODYSPLASTIC SYNDROME | 2025 | |
| 2025-09-25 | Incyte Corporation | $1,030 | Travel and Lodging | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-25 | Lilly USA, LLC | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VERZENIO Drug, Oncology | 2025 | |
| 2025-09-25 | Incyte Corporation | $123 | Food and Beverage | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-25 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-09-24 | Exelixis Inc. | $3,960 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-24 | Exelixis Inc. | $3,300 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-24 | ARRAY BIOPHARMA INC | $30 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2025 | |
| 2025-09-23 | Exelixis Inc. | $47 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-23 | Exelixis Inc. | $3 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-22 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-22 | Acrotech Biopharma Inc. | $21 | Food and Beverage | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2025 | |
| 2025-09-21 | PUMA BIOTECHNOLOGY, INC. | $29 | Food and Beverage | In-kind items and services | NERLYNX Drug, ONCOLOGY | 2025 | |
| 2025-09-18 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | $29 | Food and Beverage | In-kind items and services | ICLUSIG Drug, ONCOLOGY | 2025 | |
| 2025-09-17 | Stemline Therapeutics Inc. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Orserdu Drug, Oncology | 2025 | |
| 2025-09-17 | Stemline Therapeutics Inc. | $80 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-09-17 | Celgene Corporation | $21 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-17 | Stemline Therapeutics Inc. | $19 | Travel and Lodging | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-09-16 | Regeneron Pharmaceuticals, Inc. | $266 | Research payment | In-kind items and services | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBOD | 2025 | |
| 2025-09-16 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-16 | Celgene Corporation | $1 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-15 | Exelixis Inc. | $2,267 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-15 | Janssen Biotech, Inc. | $1,252 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-15 | Exelixis Inc. | $1,194 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-12 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-09-12 | ARRAY BIOPHARMA INC | $21 | Food and Beverage | In-kind items and services | XALKORI Drug, ONCOLOGY | 2025 | |
| 2025-09-11 | Incyte Corporation | $5,137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Monjuvi Drug, Oncology | 2025 | |
| 2025-09-11 | BeOne Medicines USA, Inc. | $2,400 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-11 | Exelixis Inc. | $125 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-11 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-10 | Exelixis Inc. | $76 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $1,436 | Travel and Lodging | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $167 | Food and Beverage | In-kind items and services | DATROWAY Biological, Oncology | 2025 | |
| 2025-09-09 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-09 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-08 | SANOFI US SERVICES INC. | $1,474 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-09-08 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-05 | Regeneron Pharmaceuticals, Inc. | $134 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-05 | Regeneron Pharmaceuticals, Inc. | $134 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-05 | Regeneron Pharmaceuticals, Inc. | $40 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-05 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-09-04 | Stemline Therapeutics Inc. | $4,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Orserdu Drug, Oncology | 2025 | |
| 2025-09-04 | Stemline Therapeutics Inc. | $1,514 | Travel and Lodging | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-09-04 | Janssen Biotech, Inc. | $601 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-04 | Gilead Sciences, Inc. | $19 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2025 | |
| 2025-09-03 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | CABLIVI Biological, Hematology | 2025 | |
| 2025-09-02 | ACCORD HEALTHCARE, INC. | $145 | Food and Beverage | In-kind items and services | Camcevi Drug, Urology Oncology – GnRH agonist for treating adults with advanced prostate cancer | 2025 |
The latest 200 records of 3,577.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-12 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $4,950 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-12-04 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,986 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-12-04 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $3,071 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-12-03 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $275 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANT | 2025 |
| 2025-11-19 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $7,117 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $4,050 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $275 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $250 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-11-10 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $700 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-11-07 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $1,458 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $225 | C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLA | 2025 |
| 2025-10-02 | Novartis Pharmaceuticals Corporation | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | $196,714 | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With | 2025 |
| 2025-10-01 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,250 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $5,287 | C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLA | 2025 |
| 2025-08-18 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $480 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2025 |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,402 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $8,039 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $1,346 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-07-21 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $4,950 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-06-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $4,950 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-06-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $1,600 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-06-02 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,808 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-05-12 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $6,410 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-04-15 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $3,071 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-04-03 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $9,051 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-03-21 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $9,560 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2025 |
| 2025-03-04 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,402 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-01-17 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,971 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-01-17 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $9,999 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2025-01-07 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $3,071 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2025 |
| 2024-12-16 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $10,611 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2024 |
| 2024-12-13 | Incyte Corporation | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | $967 | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2024 |
| 2024-10-30 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,603 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-10-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $10,450 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2024 |
| 2024-10-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,700 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2024 |
| 2024-10-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,273 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2024 |
| 2024-10-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $10,000 | Phase 3 randomized mosunetuzumab with polatuzumab in comparison with R GemOx in R R NHL | 2024 |
| 2024-10-04 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $750 | Phase 3 randomized mosunetuzumab with polatuzumab in comparison with R GemOx in R R NHL | 2024 |
| 2024-09-26 | Genentech, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $18,893 | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | 2024 |
| 2024-09-10 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $3,071 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-09-05 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $645 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2024 |
| 2024-08-07 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $2,168 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-06-18 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,288 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-05-21 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $5,346 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-05-21 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $60,086 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-03-22 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $375 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2024 |
| 2024-03-19 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $4,722 | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 x ANT | 2024 |
| 2024-03-19 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,491 | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 x ANT | 2024 |
| 2024-03-19 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $9,986 | A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 x ANT | 2024 |
| 2024-03-14 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $97 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-03-14 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $104 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-03-14 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $50 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-03-14 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $601 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-02-09 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $210 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2024 |
| 2024-02-01 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $3,150 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-02-01 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,050 | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X AN | 2024 |
| 2024-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | $1,230 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2024 |
| 2023-12-27 | Incyte Corporation | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | $967 | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 |
| 2023-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $4,325 | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2023 |
| 2023-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,000 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $275 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,000 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $825 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-12-08 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $9,986 | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X An | 2023 |
| 2023-12-08 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,491 | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X An | 2023 |
| 2023-11-30 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,491 | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Ant | 2023 |
| 2023-11-30 | Regeneron Pharmaceuticals, Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $9,986 | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Ant | 2023 |
| 2023-11-17 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $18,695 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-11-17 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,700 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-11-10 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $1,075 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-11-10 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $4,000 | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2023 |
| 2023-09-27 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $210 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-09-19 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $9,500 | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2023 |
| 2023-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $240 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-09-13 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $975 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-08-22 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $240 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-08-04 | Incyte Corporation | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | $2,500 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
| 2023-07-18 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $240 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-07-18 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $90 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $250 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-07-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $600 | A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY | 2023 |
| 2023-07-07 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $7,967 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-16 | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | Investigative Clinical Research | $9,596 | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2023 |
| 2023-06-16 | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | Investigative Clinical Research | $2,710 | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2023 |
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $3,765 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $270 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $600 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $1,335 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $2,220 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $3,150 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $634 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | INVESTIGATIVE CLINCAL RESEARCH OF INDIANA LLC | $14,193 | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINAT | 2023 |
| 2023-05-26 | Incyte Corporation | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | $8,000 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
| 2023-03-10 | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | Investigative Clinical Research | $1,099 | PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATI | 2023 |
| 2023-03-09 | Incyte Corporation | INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | $967 | PROSPECTIVE, LONGITUDINAL, NON INTERVENTIONAL STUDY OF DISEASE BURDEN AND TREATMENT OF PATIENTS WITH LOW RISK MYELOFIBRO | 2023 |
| 2023-03-08 | Incyte Corporation | HOLY CROSS HOSPITAL | $25 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
| 2023-03-08 | Incyte Corporation | HOLY CROSS HOSPITAL | $25 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
| 2023-03-08 | Incyte Corporation | HOLY CROSS HOSPITAL | $47 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
| 2023-03-08 | Incyte Corporation | HOLY CROSS HOSPITAL | $32 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
| 2023-03-08 | Incyte Corporation | HOLY CROSS HOSPITAL | $25 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Noblesville, IN, county Hamilton County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Noblesville, IN | County Hamilton County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 73,362 | 365,056 | 6,851,073 |
| Population, 2020 census P1 | 69,604 | 347,467 | 6,785,528 |
| Median age B01002 | 35.9 | 38.4 | 38.1 |
| Under 18 B01001 | 26.0% | 25.4% | 23.3% |
| 65 and over B01001 | 13.8% | 13.9% | 16.8% |
| Households B11001 | 27,115 | 137,252 | 2,716,009 |
| Foreign born B05002 | 7.9% | 10.3% | 6.3% |
| Median household income B19013 | $104,047 | $121,530 | $71,957 |
| Median family income B19113 | $125,293 | $146,219 | $90,767 |
| Per capita income B19301 | $49,199 | $60,278 | $38,351 |
| Poverty rate B17001 | 5.3% | 4.4% | 12.3% |
| Unemployment rate B23025 | 2.9% | 2.8% | 4.3% |
| Civilian labor force B23025 | 40,337 | 200,896 | 3,472,016 |
| Mean commute (minutes) B08013 | 26.6 | 25.9 | 24.1 |
| Bachelor's degree or higher B15003 | 51.6% | 61.9% | 29.5% |
| Housing units B25001 | 28,672 | 144,746 | 2,976,568 |
| Owner-occupied B25003 | 71.2% | 76.1% | 70.6% |
| Renters B25003 | 28.8% | 23.9% | 29.4% |
| Median home value B25077 | $349,700 | $405,500 | $218,200 |
| Median gross rent B25064 | $1,389 | $1,574 | $1,062 |
| White, not Hispanic B03002 | 82.2% | 78.6% | 75.4% |
| Black B03002 | 5.0% | 4.4% | 9.1% |
| Hispanic or Latino B03002 | 5.7% | 5.6% | 8.6% |
| Asian B03002 | 3.5% | 6.9% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Noblesville, IN.
Comments